Boron Neutron Capture Therapy for Newly Diagnosed Glioblastoma

We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy(BNCT)for newly-diagnosed glioblastoma(NDGB)patients, especially in combination with X-ray treatment(XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing...

Full description

Saved in:
Bibliographic Details
Published inJOURNAL OF RADIATION RESEARCH Vol. 50; no. 1; pp. 51 - 60
Main Authors Kawabata, Shinji, Miyatake, Shin-Ichi, Kuroiwa, Toshihiko, Yokoyama, Kunio, Doi, Atsushi, Iida, Kyoko, Miyata, Shiro, Nonoguchi, Naosuke, Michiue, Hiroyuki, Takahashi, Masatsugu, Inomata, Taisuke, Imahori, Yoshio, Kirihata, Mitsunori, Sakurai, Yoshinori, Maruhashi, Akira, Kumada, Hiroaki, Ono, Koji
Format Journal Article
LanguageEnglish
Published England THE JAPAN RADIATION RESEARCH SOCIETY 01.01.2009
Oxford University Press
Subjects
Adolescent
Adult
Aged
Boron neutron capture therapy
Boron Neutron Capture Therapy - methods
Brain Neoplasms - diagnosis
Brain Neoplasms - radiotherapy
Care and treatment
Chemotherapy
Combined Modality Therapy
Development and progression
Female
Glioblastoma - diagnosis
Glioblastoma - radiotherapy
Glioblastomas
Humans
Male
Middle Aged
Survival Rate
Treatment Outcome
Young Adult
Online AccessGet full text

Cover

More Information
Summary:We evaluate the clinical results of a form of tumor selective particle radiation known as boron neutron capture therapy(BNCT)for newly-diagnosed glioblastoma(NDGB)patients, especially in combination with X-ray treatment(XRT). Between 2002 and 2006, we treated 21 patients of NDGB with BNCT utilizing sodium borocaptate and boronophenylalanine simultaneously. The first 10 were treated with only BNCT(protocol 1), and the last 11 were treated with BNCT followed by XRT of 20 to 30 Gy(protocol 2) to reduce the possibility of local tumor recurrence. No chemotherapy was applied until tumor progression was observed. The patients treated with BNCT(protocol 1 plus 2)showed a significant survival prolongation compared with the institutional historical controls. BNCT also showed favorable results in correspondence with the RTOG- and EORTC-RPA subclasses. The median survival time(MST)was 15.6 months for protocols 1 and 2 together. For protocol 2, the MST was 23.5 months. The main causes of death were cerebrospinal fluid dissemination as well as local recurrence. Our modified BNCT protocol showed favorable results of patients with NDGB not only for those with good prognoses but also for those with poor prognoses.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0449-3060
1349-9157
1349-9157
DOI:10.1269/jrr.08043